Karp Capital Management Corp acquired a new stake in shares of CryoLife, Inc. (NYSE:CRY) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 10,340 shares of the medical equipment provider’s stock, valued at approximately $172,000.

A number of other institutional investors have also recently bought and sold shares of CRY. Louisiana State Employees Retirement System increased its position in CryoLife by 1.9% in the first quarter. Louisiana State Employees Retirement System now owns 11,000 shares of the medical equipment provider’s stock valued at $183,000 after buying an additional 200 shares during the last quarter. Thrivent Financial for Lutherans increased its position in CryoLife by 5.1% in the fourth quarter. Thrivent Financial for Lutherans now owns 14,500 shares of the medical equipment provider’s stock valued at $278,000 after buying an additional 700 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. increased its position in CryoLife by 14.3% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 16,207 shares of the medical equipment provider’s stock valued at $310,000 after buying an additional 2,032 shares during the last quarter. Comerica Bank increased its position in CryoLife by 6.3% in the fourth quarter. Comerica Bank now owns 28,727 shares of the medical equipment provider’s stock valued at $550,000 after buying an additional 1,714 shares during the last quarter. Finally, Wells Fargo & Company MN increased its position in CryoLife by 16.5% in the first quarter. Wells Fargo & Company MN now owns 31,042 shares of the medical equipment provider’s stock valued at $517,000 after buying an additional 4,399 shares during the last quarter. Institutional investors and hedge funds own 68.19% of the company’s stock.

Shares of CryoLife, Inc. (NYSE CRY) opened at 19.60 on Wednesday. The stock has a market cap of $651.90 million, a P/E ratio of 63.64 and a beta of 0.99. CryoLife, Inc. has a 52-week low of $11.81 and a 52-week high of $20.30. The firm’s 50 day moving average price is $18.79 and its 200 day moving average price is $17.93.

CryoLife (NYSE:CRY) last issued its quarterly earnings results on Wednesday, April 26th. The medical equipment provider reported $0.09 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.04 by $0.05. The business had revenue of $45.10 million for the quarter, compared to analysts’ expectations of $44.64 million. CryoLife had a net margin of 5.73% and a return on equity of 7.77%. The company’s revenue was up 4.9% compared to the same quarter last year. During the same quarter last year, the company posted $0.10 EPS. On average, analysts expect that CryoLife, Inc. will post $0.43 EPS for the current year.

WARNING: This story was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this story on another website, it was stolen and republished in violation of United States & international copyright and trademark law. The legal version of this story can be read at https://www.watchlistnews.com/10340-shares-in-cryolife-inc-cry-acquired-by-karp-capital-management-corp/1431180.html.

Several research firms recently commented on CRY. Zacks Investment Research upgraded CryoLife from a “hold” rating to a “buy” rating and set a $21.00 price objective on the stock in a research note on Thursday, June 8th. Northland Securities restated a “buy” rating and set a $23.50 target price on shares of CryoLife in a research report on Friday, April 28th. Five research analysts have rated the stock with a buy rating, CryoLife presently has an average rating of “Buy” and an average price target of $20.80.

In other news, VP Amy Horton sold 9,577 shares of CryoLife stock in a transaction on Tuesday, June 27th. The shares were sold at an average price of $20.00, for a total transaction of $191,540.00. Following the transaction, the vice president now owns 112,282 shares in the company, valued at approximately $2,245,640. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 6.00% of the company’s stock.

About CryoLife

CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.

Want to see what other hedge funds are holding CRY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CryoLife, Inc. (NYSE:CRY).

Institutional Ownership by Quarter for CryoLife (NYSE:CRY)

Receive News & Ratings for CryoLife Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoLife Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.